LEO Pharma Signs an Option Agreement with Ubiquigent to Access its Two Novel Therapies

 LEO Pharma Signs an Option Agreement with Ubiquigent to Access its Two Novel Therapies

LEO Pharma Signs an Option Agreement with Ubiquigent to Access its Two Novel Therapies

Shots:

  • Ubiquigent to receive up front, option exercise fee and milestone payment. Leo Pharma to get an option to access two novel therapies
  • The partnership will strengthen Leo Pharma’s research capabilities and disease understanding and extending its expertise in medical dermatology worldwide
  • The option agreement follows 2018 agreement signed b/w Ubiquigent and LEO Pharma to evaluate a collection of Ubiquigent’s novel compounds across LEO Pharma’s in-house disease-relevant assays

Click here to­ read full press release/ article | Ref: Businesswire | Image: Julia

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post